FHIT expression and hypermethylation in esophageal squamous cell carcinoma

International Journal of Molecular Medicine

Volumn 11, Issue 4, 2003, Pages 441-447

  Noguchi, Tsuyoshi ^a   Takeno, Shinsuke ^a   Kimura, Yasuhiko ^a   Uchida, Yuzo ^a   Daa, Tsutomu ^a   Yokoyama, Shigeo ^a   Gabbert, Helmut E ^b   Mueller, Wolfram ^b  

^a OITA UNIVERSITY   (Japan)

^b HEINRICH HEINE UNIVERSITY   (Germany)

Author keywords

Esophageal cancer; FHIT; Lymphatic spread; Methylalion; Prognosis; Tumor invasion

Indexed keywords

FRAGILE HISTIDINE TRIAD PROTEIN; ACID ANHYDRIDE HYDROLASE; TUMOR PROTEIN;

ADULT; AGED; ARTICLE; CANCER GROWTH; CANCER PROGNOSIS; CONTROLLED STUDY; CPG ISLAND; DNA METHYLATION; ESOPHAGEAL SQUAMOUS CELL CARCINOMA; ESOPHAGUS RESECTION; FEMALE; FHIT GENE; GENE DELETION; GENE EXPRESSION; HUMAN; HUMAN TISSUE; IN VIVO STUDY; LYMPH NODE DISSECTION; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; PROMOTER REGION; PROTEIN EXPRESSION; TUMOR INVASION; BIOSYNTHESIS; ESOPHAGUS TUMOR; GENE EXPRESSION REGULATION; GENETICS; IMMUNOHISTOCHEMISTRY; METABOLISM; MIDDLE AGED; PATHOPHYSIOLOGY; SQUAMOUS CELL CARCINOMA;

ACID ANHYDRIDE HYDROLASES; ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, SQUAMOUS CELL; CPG ISLANDS; DNA METHYLATION; ESOPHAGEAL NEOPLASMS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; NEOPLASM PROTEINS; PROMOTER REGIONS (GENETICS);

EID: 0141942025     PISSN: 11073756     EISSN: 1791244X     Source Type: Journal    
DOI: 10.3892/ijmm.11.4.441     Document Type: Article

References (50)

1. Pisani P, Parkin DM, Bray F and Fcrlay J: Estimates of the worldwide mortality from 25 cancers in 1990. Int J Cancer 83:18-29. 1999.
2. Ribeiro U Jr, Finkelstein SD, Safatle-Ribeiro AV, Landreneau RJ, Clarke MR. Bakker A, Swalsky PA, Gooding WE and Posner MC: p53 sequence analysis predicts treatment response and outcome of patients with esophageal carcinoma. Cancer 83:7-18, 1998.
3. Ikeda G, Isaji S, ChandraDas B. Watanabe M and Kawarada Y: Prognostic significance of biologic factors in squamous cell carcinoma of the esophagus. Cancer 86:1396-1405, 1999.
4. Lam KY, Tsao SW, Zhang D, Law S, He D, Ma L and Wong J: Prevalence and predictive value of p53 mutation in patients with oesophageal squamous cell carcinomas: a prospective clinicopathological study and survival analysis of 70 patients. Int J Cancer 74:212-219, 1997.
5. Coggi G, Bosari S, Roncalli M, Graziani D, Bossi P, Viale G, Buffa R, Ferrero S, Piazza M, Blandamura S, Segalin A, Bonavina L and Peracchia A: p53 protein accumulation and p53 gene mutation in esophageal carcinoma. A molecular and immunohistochemical study with clinicopathologic correlations. Cancer 79:425-432, 1997.
6. Murakami S, Uchida Y, Takeno S, Noguchi T, Matsumoto K and Shimoda H: Expression of PCNA and p53 in esophageal dysplasia and esophageal carcinoma. Surg Today 27:593-599, 1997.
7. Takeno S, Noguchi T, Kikuchi R, Uchida Y, Yokoyama S and Miiller W: Prognostic value of cyclin Bl in patients with esophageal squamous cell carcinoma. Cancer 94:2874-2881, 2002.
8. Ohta M, Inoue H, Cotticelli MG, Kastury K, Baffa R, Palazzo J, Siprashvili Z, Mori M, McCue P, Druck T, Croce CM and Huebner K: The FHIT gene, spanning the chromosome 3pl4.2 fragile site and renal carcinoma-associated t (3;8) breakpoint, is abnormal in digestive tract cancers. Cell 84:587-597, 1996.
9. Sozzi G, Veronese ML, Negrini M, Baffa R, Cotticelli MG, Inoue H, Tornielli S, Pilotti S, De Gregorio L, Pastorino U, Pierotti MA, Ohta M, Huebner K and Croce CM: The FHIT gene 3pl4.2 is abnormal in lung cancer. Cell 85:17-26, 1996.
10. Fong KM, Bieslerveld EJ, Virmani A, Wistuba I, Sekido Y, Bader SA, Ahmadian M, Ong ST, Rasool FV, Zimmerman PV, Giaccone G, Gazdar AF and Minna JD: FHIT and FRA3B 3pl4.2 allele loss arc common in lung cancer and preneoplastic bronchial lesion and are associated with cancer-related FHIT cDNA splicing aberrations. Cancer Res 57:2256-2267, 1997.
11. Sozzi G, Alder H, Tornielli S, Corlctto V, Baffa R, Veronese ML, Negrini M, Pilotti S, Pierotti MA, Huebner K and Croce CM: Aberrant FHIT transcripts in Merkel cell carcinoma. Cancer Res 56:2472-2474, 1996.
12. Wistuba II, Behrens C, Virmani AK, Mele G, Milchgrub S, Girard L, Fondon JW III, Garner HR, McKay B, Latif F, Lerman MI, Lam S, Gazdar AF and Minna JD: High resolution chromosome 3p allelotyping of human lung cancer and preneoplastic/preinvasive bronchial epithelium reveals multiple, discontinuous sites of 3p allele loss and three regions of frequent breakpoints. Cancer Res 60:1949-1960, 2000.
13. Yanagisawa K, Kondo M, Osada H, Uchida K, Takagi K, Masuda A, Takahashi T and Takahashi T: Molecular analysis of the FHIT gene at 3pl4.2 in lung cancer cell lines. Cancer Res 56:5579-5582, 1996.
14. Negrini M, Monaco C, Vorechovsky I, Ohta M, Druck T, Baffa R, Huebner K and Corce C: The FHIT gene at 3pl4.2 is abnormal in breast carcinomas. Cancer Res 56:3173-3179, 1996.
15. Ahmadian M, Wistuba II, Fong KM, Behrens C, Kodagoda DR, Saboorian MH, Shay J, Tomlinson GE, Blum J, Minna JD and Gazdar AF: Analysis of the FHIT gene and FRA3B region in sporadic breast cancer, preneoplastic lesions, and familial breast cancer probands. Cancer Res 57:3664-3668, 1997.
16. Virgilio L, Shuster M, Gollin SM, Veronese ML, Ohta M, Huebner K and Croce CM: FHIT gene alterations in head and neck squamous cell carcinomas. Proc Natl Acad Sci USA 93:9770-9775, 1996.
17. Moa L, Fan YH, Lotan R and Hong WK: Frequent abnormalities of FHIT, a candidate tumor suppressor gene, in head and neck cancer cell lines. Cancer Res 56:5128-5131, 1996.
18. Krivak TC, McBroom JW, Scidmen J, Venzon D, Crothers B, MacKoul PJ, Rose GS, Carlson JW and Birrer MJ: Abnormal fragile histidine triad (FHIT) expression in advanced cervical carcinoma: a poor prognostic factor. Cancer Res 61:4382-4385, 2001.
19. Yang Q, Yoshimura G, Suzuma T, Tamaki T, Umemura T, Nakamura M, Nakamura Y, Wang X, Mori I, Sakurai T and Kakudo K: Clinicopathological significance of fragile histidine triad transcription protein expression in breast carcinoma. Clin Cancer Res 7:3869-3873, 2001.
20. Ramp U, Caliskan E, Ebert T, Karagiannidis C, Willers R, Gabbert HE and Gerharz CD: FHIT expression in clear cell renal carcinomas: versatility of protein levels and correlation with survival. J Pathol 196:430-436, 2002.
21. Capuzzi D, Santoro E, Hauck WW, Kovatich AJ, Rosato FE, Baffa R, Huebner K and McCue PA: Fhit expression in gastric adenocarcinoma: correlation with disease stage and survival. Cancer 88:24-34, 2000.
22. Nelson HI1, Wiencke JK, Gunn L, Wain JC, Christiani DC and Kelsey KT: Chromosome 3p 14 alterations in lung cancer: evidence that FHIT exon deletion is a target of tobacco carcinogens and asbestos. Cancer Res 58:1804-1807, 1998.
23. Stein CK, Glover TW, Palmer JL and Glisson BS: Direct correlation between FRA3B expression and cigarette smoking. Genes Chromosomes Cancer 34:333-340, 2002.
24. Blot WJ: Esophageal cancer trends and risk factors. Semin Oncol 21:403-410, 1994.
25. Mayer RJ: Overview: the changing nature of esophageal cancer. Chest 103:404S-405S, 1993.
26. Baylin SB, Herman JG, Graff JR, Vertino PM and Issa JP: Alterations in DNA methylation: a fundamental aspect of neoplasia. Adv Cancer Res 72:141-196, 1998.
27. Costello JF, Fruhwald MC, Smiraglia DJ, Rush LJ, Robertson GP, Gao X, Wright FA, Feramisco JD, Peltomaki P, Lang JC, Schuller DE, Yu L, Bloomfield CD, Caligiuri MA, Yates A, Nishikawa R, Su Huang H, Petrelli NJ, Zhang X, O'Dorisio MS, Held WA, Cavenee WK and Plass C: Aberrant CpG-island methylation has non-random and tumor-lype-specific patterns. Nat Genet 24:132-138, 2000.
28. Momparler RL and Bovenzi V: DNA methylation and cancer. J Cell Physiol 183:145-154, 2000.
29. Herman JG, Graff JR, Myohanen S, Nelkin BD and Baylin SB: Methylation-specific PCR a novel PCR assay for methylation status of CpG islands. Proc Natl Acad Sci USA 93:9821-9826, 1996.
30. Zöchbauer-Müller S, Fong KM, Maitra A, Lam S, Geradts J, Ashfaq R, Virmani AK, Milchgrub S, Gazdar AF and Minna JD: 5' CpG island methylation of the FHIT gene is correlated with loss of gene expression in lung and breast cancer. Cancer Res 61:3581-3585, 2001.
31. Sobin LH and Wittekind CH (eds): In: UICC TNM Classification of Malignant Tumours. 5th edition. Wiley-Liss, New York, pp54-58, 1997.
32. Mao L, Lee JS, Kurie JM, Fan YH, Lippman SM, Lee JJ, Ro JY, Broxson A, Yo R, Morice RC, Kemp BL, Khun FR, Walsh GL, Hittelman WN and Hong WK: Clonal genetic alterations in the lungs of current and former smokers. J Natl Cancer Inst 89:857-862, 1997.
33. Marchetti A, Pellegrini S, Sozzi G, Bertacca G, Gaeta P, Buttitta F, Carnicelli V, Griseri P, Chella A, Angeletti CA, Pierotti M and Beriacqua G: Genetic analysis of lung tumors of non-smoking subjects: p53 gene mutations are constantly associated with loss of heterozygosity. Br J Cancer 78:73-78, 1998.
34. Sozzi G, Sand L, Gregorio LD, Marchctti A, Musso K, Buttitta F, Tornielli S, Pellegrini S, Veronese ML, Manetti G, Incarbone M, Chella A, Angeletti CA, Pastorine U, Hvebner K, Berilaqua G, Pilotti S, Croce CM and Pierotti MA: Association between cigarette smoking and FHIT gene alterations in lung cancer. Cancer Res 57:2121-2123, 1997.
35. Tomizawa Y, Nakajima T, Kohno T, Saito R, Yamaguchi N and Yokota J: Clinicopathological significance of FHIT protein expression in stage I non-small cell lung carcinoma. Cancer Res 58:5478-5483, 1998.
36. Mori M, Mimori K, Shiraishi T, Alder H, Inoue H, Tanaka Y, Sugimachi K, Huebner K and Croce CM: Altered expression of Fhit in carcinoma and precarcinomatous lesions of the esophagus. Cancer Res 60:1177-1182, 2000.
37. Pack SD, Karkera JD, Zhuang Z, Pak ED, Balan KV, Hwu P, Park WS, Pham T, Ault DO, Glaser M, Liotta L, Detera-Wadleigh SD and Wadleigh RG: Molecular cytogenetic fingerprinting of esophageal squamous cell carcinoma by comparative genomic hybridization reveals a cocsistent pattern of chromosomal alterations. Genes Chromosomes Cancer 25:160-168, 1999.
38. Hu N, Roth MJ, Emmert-Buck MR, Tang ZZ, Polymeropolous M, Wang QH, Goldstein AM, Han XY, Dawsey SM, Ding T, Giffen C and Taylor PR: Allelic loss in esophageal squamous cell carcinoma patients with and without family history of upper gastrointestinal tract cancer. Clin Cancer Res 5:3476-3482, 1999.
39. Tada K, Oka M, Tangoku A, Hayashi H, Oga A and Sasaki K: Gains of 8q23-qter and 20q and loss of 1 lq22-qter in esophageal squamous cell carcinoma associated with lymph node metastasis. Cancer 88:268-273, 2000.
40. Tada K, Oka M, Hayashi H, Tangoku A, Oga A and Sasaki K: Cytogenetic analysis of esophageal squamous cell carcinoma cell lines by comparative genomic hybridization: relationship of cytogenetic aberrations to in vitro cell growth. Cancer Genet Cytogenet 117:108-112, 2000.
41. Yen CC, Chen YJ, Chen JT, Hsia JY, Chen PM, Liu JH, Fan FS, Chiou TJ, Wang WS and Lin CH: Comparative genomic hybridization of esophageal squamous cell carcinoma: correlation between chromosomal aberrations and disease progression/prognosis. Cancer 92:2769-2777, 2001.
42. Tanaka H, Shimada Y, Harada H, Shinoda M, Hatooka S. Imamura M and Ishizaki K: Methylation of the 5' island of the FHIT gene is closely associated with transcriptional inactivation in esophageal squamous cell carcinomas. Cancer Res 58:3429-3434, 1998.
43. Shimada Y. Sato F. Watanabc G. Yamasaki S, Kato M, Maeda M and Imamura M: Loss of fragile histidine triad gene expression is associated with progression of esophageal squamous cell carcinoma, but not with the patient's prognosis and smoking history. Cancer 89:5-11. 2000.
44. Kitamura A, Yashima K, Okamoto E, Andachi H, Hosoda A, Kishimoto Y, Shiota G, Ito H, Kaibara N and Kawasaki H: Reduced fhit expression occurs in the early stage of esophageal tumorigenesis: no correlation with p53 expression and apoptosis. Oncology 61:205-211, 2001.
45. Siprashvili Z, Sozzi G, Barnes LD, McCue P, Robinson AK, Eryomin V, Sard L, Tagliabue E, Greco A, Fusetti L, Schwartz G, Pierotti MA, Croce CM and Huebner K: Replacement of Fhit in cancer cells suppresses tumorigenicity. Proc Natl Acad Sci USA 94:13771-13776. 1997.
46. Sard L, Accornerd P. Tornielli S, Delia D. Bunone G, Campiglio M, Colombo MP, Gramegna M, Croce CM, Pierotti MA and Sozzi G: The tumor-suppressor gene FHIT is involved in the regulation of apoptosis and in cell cycle control. Proc Natl Acad Sci USA 96:8489-8492, 1999.
47. Ji L. Fang B. Yen N. Fong K, Minna JD and Roth JA: Induction of apoptosis and inhibition of tumorigenicity and tumor growth by adenovirus vector-mediated fragile histidine triad (FHIT) gene overexpression. Cancer Res 59:3333-3339, 1999.
48. Ishii H. Dumon KR. Vecchione A. Trapasso F, Mimori K. Alder H, Mori M, Sozzi G, Baffa R, Huebner K and Croce CM: Effect of adenovirus transduction of the fragile histidine triad gene into esophageal cancer cells. Cancer Res 61:1578-1584, 2001.
49. Gemma A, Hagiwara K, Ke Y, Burke LM, Khan MA, Nagashima M, Bennett WP and Harris CC: FHIT mutations in human primary gastric cancer. Cancer Res 57:1435-1437, 1997.
50. Zou TT, Lei J, Shi YQ. Yin J, Wang S, Souza RF, Kong D, Shimada Y, Smolinski KN, Grcenwald BD, Abraham JM, Harpaz N and Meltzer SJ: FHIT gene alterations in esophageal cancer and ulcerative colitis (UC). Oncogene 15:101-105, 1997.